Comparing Durvalumab vs Pembrolizumab

View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions.
Durvalumab	Pembrolizumab	Enter another drug to compare

View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions.
Durvalumab	Pembrolizumab	Enter another drug to compare
Prescription only Prescribed for Small Cell Lung Cancer, Non Small Cell Lung Cancer, Biliary Tract Tumor, Hepatocellular Carcinoma, Endometrial Cancer, Bladder Cancer. Durvalumab may also be used for purposes not... View more	Prescription only Prescribed for Bladder Cancer, Cervical Cancer, Breast Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more	Related suggestions Non Small Cell Lung Cancer Tagrisso Keytruda Opdivo Alimta Avastin Nivolumab Endometrial Cancer Megestrol Keytruda Lenvima Anastrozole Imfinzi Provera Hepatocellular Carcinoma Nexavar Sorafenib Opdivo Keytruda Nivolumab Stivarga Bladder Cancer Cisplatin Mitomycin Keytruda Imfinzi Atezolizumab Mutamycin
More about Durvalumab	More about Pembrolizumab
Ratings & Reviews
Durvalumab has an average rating of 8.0 out of 10 from a total of 7 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 0% reported a negative effect.	Pembrolizumab has an average rating of 5.2 out of 10 from a total of 280 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 45% reported a negative effect.
View all 7 reviews	View all 280 reviews
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified.
View all Durvalumab side effects	Fatigue (11.8%) Weakness (7.1%) Shortness of breath (6.4%) Tiredness (6.4%) Loss of appetite (5.7%) Itching (4.6%) Diarrhea (4.3%) View all Pembrolizumab side effects
Drug Class
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)	Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Generic Availability
N/A	N/A
Pricing and Coupons * Prices are without insurance
We could not find an exact match for this medicine. Try searching the Price Guide directly.	We could not find an exact match for this medicine. Try searching the Price Guide directly.
Get free Discount Card	Get free Discount Card

Dosage Forms
N/A	N/A
Brand Names
Imfinzi	Keytruda
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value.
408 hours	624 hours
CSA Schedule ¹ View glossary of CSA terms
N Not a controlled drug Is not subject to the Controlled Substances Act.	N Not a controlled drug Is not subject to the Controlled Substances Act.
Pregnancy Category
Summary unavailable. See the full pregnancy warnings document.	D Category D Positive evidence of risk See the full pregnancy warnings document.
Drug Interactions
A total of 622 drugs are known to interact with Durvalumab: 25 major drug interactions (76 brand and generic names) 596 moderate drug interactions (2119 brand and generic names) 1 minor drug interactions (2 brand and generic names)	A total of 588 drugs are known to interact with Pembrolizumab: 3 major drug interactions (6 brand and generic names) 585 moderate drug interactions (2057 brand and generic names)
Alcohol/Food/Lifestyle Interactions
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider.	No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease Interactions
Adrenal insufficiency Colitis Diabetes Infections Liver dysfunction Renal dysfunction Thyroid disorders Durvalumab – pneumonitis HSCT Myasthenia gravis Organ transplant	Immune system disorder HSCT Myasthenia gravis Organ transplant Colitis Hepatic impairment Multiple myeloma Pneumonitis Thyroid disease
First Approval Date
May 01, 2017	N/A
WADA Class View classifications
N/A	N/A
More Information
Side effects Drug interactions Dosage Pregnancy warnings Breastfeeding warnings Support group En español	Side effects Drug interactions Dosage Pregnancy warnings Breastfeeding warnings Support group En español
Patient Resources
Durvalumab uses	Pembrolizumab uses
Professional Resources
Monograph (AHFS) Prescribing information	Monograph (AHFS) Prescribing information
Related Treatment Guide
Small Cell Lung Cancer Non Small Cell Lung Cancer Biliary Tract Tumor Hepatocellular Carcinoma Endometrial Cancer Bladder Cancer	Bladder Cancer Cervical Cancer Breast Cancer Biliary Tract Tumor Colorectal Cancer Endometrial Cancer Esophageal Carcinoma Gastric Cancer Head and Neck Cancer Hepatocellular Carcinoma Hodgkin's Lymphoma Malignant Pleural Mesothelioma Melanoma Melanoma - Metastatic Merkel Cell Carcinoma Non Small Cell Lung Cancer Ovarian Cancer Primary Mediastinal Large B-cell Lymphoma Renal Cell Carcinoma Solid Tumors Squamous Cell Carcinoma Urothelial Carcinoma show all

¹ The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Comparing Durvalumab vs Pembrolizumab

Further information

Compare Drugs